沃华医药(002107.SZ)：预计2025年净利润同比增长119.76%～215.9%

Core Viewpoint - Wowo Pharmaceutical (002107.SZ) expects a net profit attributable to shareholders of 80 million to 115 million yuan for 2025, representing a year-on-year growth of 119.76% to 215.90% [1] Financial Performance - The net profit after deducting non-recurring gains and losses is projected to be between 75 million and 105 million yuan, indicating a year-on-year increase of 118.38% to 205.74% [1] Strategic Initiatives - The company has implemented a refined management approach characterized by "practical, detailed, strict, and simple" requirements, effectively controlling costs [1] - The strategic focus on "reducing costs and increasing sales, efficiency, and cash flow" has been fully executed [1] Marketing and Sales Development - The company has strengthened academic promotion and product branding, continuously unlocking product potential [1] - Marketing reforms have solidified results, with a more professional and mature sales team adapting to market competition following the entry of Wowo® Xinkeshu Tablets into centralized procurement [1] - The hospital market has been consolidated and developed, leveraging brand and academic advantages to achieve precise extension and efficient coverage in the outpatient market, establishing a collaborative development model of "hospital + outpatient" [1]